Reports Q4 revenue $76.3M, consensus $75.89M. “We generated strong sales growth in the fourth quarter, consistent with our preliminary sales announcement, and profitability, driven by strength in APAC and sequential growth in EMEA,” said Tom Frinzi, President and CEO of STAAR Surgical. “For fiscal 2023, every large market delivered positive sales growth. Our ICL unit growth exceeded refractive industry growth by over 25 points for the third year in a row. Our 22% global ICL sales growth in the quarter included 30% growth in China and 18% in EMEA. As we enter 2024, we see encouraging end-market ICL sales trends and are affirming our fiscal 2024 net sales outlook of $335 million to $340 million.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on STAA:
- Is STAA a Buy, Before Earnings?
- Staar Surgical announces strategic pact in U.S. with SharpeVision, no terms
- Staar Surgical price target lowered to $31 from $33 at Canaccord
- Fly Insider: Athira Pharma, Microstrategy among week’s notable insider trades
- Staar Surgical sees FY24 revenue $335M -$340M, consensus $366.8M
